Agenda

National Head & Neck Oncology Meeting | Friday 16th September 2022

TIME	TOPIC	SPEAKER
08.30-09.30	Welcome and Registration
09.30-09.35	Welcome and Opening Remarks	Dr Mehmet Sen, Leeds Cancer Centre
09.35-10.35	Presentations Based on Recent Research Papers from UK	Chair: Robin Prestwich
09.35-09.45	1. Pre-treatment lymphocyte count predicts benefit from concurrent cisplatin with radiotherapy in oropharynx cancer	James Price, The Christie Hospital, Manchester
09.45-09.55	2. Mildly hypofractionated radiotherapy does not compromise swallowing outcomes compared to conventional fractionation in oropharynx cancer: a multi-centre study	Zsuzsie Iyizoba, Leeds
09.55-10.15	3. COMPARE Arm 1 v Arm 3 (modified fraction)	Paul Sanghera, Birmingham
10.15 - 10.25	4. TBC	TBC
10.25 - 10.35	5. HNSCC Unknown primary: Involved neck only versus mucosal irradiation: Glasgow experience	Wai Yan Poon, Glasgow
10.35-11.00	COFFEE BREAK
11.00-11.35	Unknown primary, HNSCC	Chair: Claire Patterson
11.00-11.20	MOSES outcomes and the recent ENT UK H&N Cancer Unknown Primary Consensus	Vin Paleri, Royal Marsden, London
11.20-11.35	My clinical radiotherapy practice after a ‘MALTectomy’	Shree Bhide, Royal Marsden, London
11.35-12.30	Oropharynx cancer: Current role of transoral surgery	Chair: Mehmet Sen
11.35-11.55	Current role of TORS - the surgical perspective	Christian Simon, Lausanne, EORTC H&N Chair
11.55-12.15	Current role of transoral surgery and adjuvant therapy - the radiation oncology perspective	Mererid Evans and/or Richard Webster, Velindre, Cardiff
12.15-12.30	The Newcastle Experience of TORS +/- adjuvant treatment	James O’Hara, Newcastle
12.30-13.30	LUNCH
13.30-14.00	Artificial intelligence in H&N oncology	Chair: Teresa Guerrero Urbano
13.30-13.40	Introduction to AI opportunities	Teresa Guerrero Urbano, Guy’s and St.Thomas’s, London
13.40-14.00	Developing AI models for workflow acceleration and decision support in H&N Radiotherapy	Raj Jena, Addenbrookes, Cambridge
14.00-14.50	Systemic and Immunotherapy	Chair: Dr Rob Metcalfe, The Christie Hospital, Manchester
14.00-14.15	UK pembrolizumab experience in HNSCC	Anthony Kong, UCL, London
14.15-14.25	Scottish experience of pembrolizumab and chemotherapy	Christina Wilson, The Beatson Cancer Centre, Glasgow
14.25-14.40	Combining RT and IO in HNSCC	Kevin Harrington, Royal Marsden, London
14.40-14.50	Discussion	All
14.50-15.10	COFFEE BREAK
15.10-15.25	Current UK NCRI trial update and future directions	Martin Forster, UCL, London
15.25-15.40	Nasopharynx cancer: toxicity and role of protons	Chair: Caroline Brammer, Liverpool
15.25-15.55	Toxicity of (chemo)radiotherapy for nasopharyngeal cancer: UK experience	Romelie Rieu, Royal Marsden Hospital, National CTRad Proton Beam Radiotherapy Fellow
15.40-15.55	Protons for nasopharynx cancer: commissioning for evaluation study, radiotherapy protocol	Andy McPartlin, The Christie Hospital, Manchester
15.55-16.15	Rehabilitation	Chair: Caroline Brammer, Liverpool
	Radiation induced fibrosis&lymphoedema; early identification, management and rehabilitation	Emma Hallam, Nottingham
16.15-17.00	PANEL: H&N Case discussions	Chair: Christina Wilson, The Beatson Cancer Centre, Glasgow Gill Barnett, Addenbrooks, Cambridge Dinos Geropantas, Norwich
17.00-17.05	Meeting Summary and Close	Mehmet Sen

Please note this agenda may be subject to changes.
This course provides 6 CPD credits in accordance with the CPD Scheme of The Royal College of Radiologists.